Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Pharmacokinetic consequences of a citalopram treatment discontinuation.
In this pilot study , the pharmacokinetics of citalopram ( CIT ) were examined in five hospitalized depressed patients after an abrupt discontinuation of a treatment with 40 mg/d of this selective serotonin reuptake inhibitor ( SSRI ) .  During the 8-day study period , clinical ratings were regularly carried out . Between days 5 and 8 , the patients were treated with clomipramine ( 75 mg/d ) . The enantiomers of CIT and its metabolites , demethyl-CIT ( DCIT ) and CIT-propionic acid derivative ( CIT-PROP ) , were measured repeatedly from day 0 to day 8 by a stereoselective high-performance liquid chromatography ( HPLC ) procedure . The following drug plasma half-lives were measured ( means + /- SD ) : R-CIT : 66+/-11 h ; S-CIT : 42+/-13 h ; R-DCIT : 228+/-148 h ; S-DCIT : 93+/-35 h ; R-CIT-PROP : 82+/-31 h ; S-CIT-PROP : 186+/-93
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .